SAGE Therapeutics Inc
NASDAQ:SAGE

Watchlist Manager
SAGE Therapeutics Inc Logo
SAGE Therapeutics Inc
NASDAQ:SAGE
Watchlist
Price: 8.68 USD -0.23%
Market Cap: 543.5m USD

Net Margin
SAGE Therapeutics Inc

-747.6%
Current
-4 000%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-747.6%
=
Net Income
-354.4m
/
Revenue
47.4m

Net Margin Across Competitors

SAGE Therapeutics Inc
Glance View

Market Cap
542.9m USD
Industry
Biotechnology

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

SAGE Intrinsic Value
20.48 USD
Undervaluation 58%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-747.6%
=
Net Income
-354.4m
/
Revenue
47.4m
What is the Net Margin of SAGE Therapeutics Inc?

Based on SAGE Therapeutics Inc's most recent financial statements, the company has Net Margin of -747.6%.

Back to Top